Curtis Gale Oltmans is CLO at ARRAY BIOPHARMA INC (ARRY). They have made 4 open-market trades across 2 companies since 2019, most recently 2025-12-15.
CIK 0001714982
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2021, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FULC | SELL · 10b5-1 | 2025-12-15 | 2025-12-17 | $12.92 | $45K | -7.1% | -17.0% | -39.3% |
| FULC | BUY | 2021-06-28 | 2021-06-29 | $9.01 | $10K | -1.0% | -24.8% | +174.0% |
| ARRY | SELL | 2019-02-05 | 2019-02-07 | $20.00 | $800K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2019-01-25 | 2019-01-29 | $18.00 | $253K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL · 10b5-1 | 2019-01-18 | 2019-01-23 | $18.00 | $23K | +33.9% | +23.6% | +23.6% |
| ARRY | SELL | 2019-01-15 | 2019-01-17 | $18.06 | $712K | +33.9% | +23.6% | +23.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.